Identification of potential prognostic biomarkers of thymoma with myasthenia gravis based on serum proteomics
HLA-A, C5, and SELL may be potential prognostic biomarkers of TMG. This study may provide a more accurate prognostic risk assessment of TMG patients to help clinicians better individualize the initial treatment regimen for patients with different risk stratification, plan a more reasonable frequency of follow-up visits, and make more precise maintenance treatment decisions, thereby improving the overall prognosis of TMG patients.
Authors
- Guoyan Qi (ORCID: https://orcid.org/0000-0001-9218-3219)
- Peng Liu (ORCID: https://orcid.org/0000-0002-1849-9634)
- Xiaoting Lin
Institutions
- Hebei Medical University (CN)
- Hebei Chemical and Pharmaceutical College (CN)
- Hebei General Hospital (CN)
- First Hospital of Shijiazhuang (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1580219
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China